Cell surface expression of HLA-E molecules on PBMC from a TAP1-deficient patient

Tissue Antigens

Volumn 53, Issue 3, 1999, Pages 292-295

  Furukawa, H ^a,b   Yabe, Toshio ^a   Akaza, T ^a   Tadokoro, K ^a   Tohma, S ^b   Inoue, T ^b   Tokunaga, K ^c   Yamamoto, K ^b   Geraghty, D E ^d   Juji, T ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bare lymphocyte syndrome; Cell surface expression; HLA class I deficiency; HLA E; TAP1

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CELL SURFACE; GENE MUTATION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIGENS, CD14; ANTIGENS, CD19; ANTIGENS, CD3; ATP-BINDING CASSETTE TRANSPORTERS; B-LYMPHOCYTES; CELL LINE; CELL TRANSFORMATION, VIRAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; MAJOR HISTOCOMPATIBILITY COMPLEX; SURFACE PROPERTIES;

EID: 0032991394     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.1999.530310.x     Document Type: Article

References (13)

1. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998: 10: 4951-60.
2. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998: 8: 1-10.
3. Lee N, Llano M, Carretero M et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998: 95: 5199-204.
4. Braud VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998: 391: 795-9.
5. Llano M, Lee N, Navarro F et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998: 28: 2854-63.
6. Furukawa H, Murata S, Yabe T et al. Splice acceptor site mutation of the TAP1 gene in HLA class I deficiency. J Clin Invest 1999: in press.
7. Furukawa H, Yabe T, Watanabe K et al. Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (Bare lymphocyte syndrome type I). Hum Immunol 1999: 60: 32-40.
8. Geraghty DE, Stockschleader M, Ishitani A, Hansen JA. Polymorphism at the HLA-E locus predates most HLA-A and -B polymorphism. Hum Immunol 1992: 33: 174-84.
9. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992: 356: 443-6.
10. Henderson RA, Michel H, Sakaguchi K et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992: 255: 1264-6.
11. Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell 1994: 79: 649-58.
12. Aldrich CJ, Waltrip R, Hermel E et al. T cell recognition of QA-1b antigens on cells lacking a functional Tap-2 transporter. J Immunol 1992: 149: 3773-7.
13. Tompkins SM, Kraft JR, Dao CT, Soloski MJ, Jensen PE. Transporters associated with antigen processing (TAD)-independent presentation of soluble insulin to alpha/beta T cells by the class Ib gene product, Qa-1 (b). J Exp Med 1998: 188: 961-71.